

New issue of Xintelling No. 2 2025

[Read Xintela´s newsletter in English here](#)

Contacts

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: evy@xintela.se

Medicon Village

223 81 Lund, Sweden

www.xintela.se

About Xintela

Xintela ([XINT](#)) is a publicly-traded clinical-stage biopharma company, that develops cutting edge medical products in stem cell therapy and targeted cancer therapy. Xintela's proprietary technology uses the stem cell marker integrin $\alpha10\beta1$ to select and quality-assure the stem cell product XSTEM®, which is in clinical development for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers. Xintela's in-house GMP-facility manufactures XSTEM and generates revenues by providing process development and manufacturing of other cell therapies. Xintela's wholly owned subsidiary Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin $\alpha10\beta1$. TARG9, an Antibody-Drug Conjugate (ADC), and TARG10, a function blocking antibody, are in preclinical development for the treatment of aggressive, difficult to treat cancers including triple-negative breast cancer and brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm. Xintela's Certified Adviser is Tapper Partners AB.

Image Attachments

[Xintelling Oct 2025 EN](#)

Attachments

[New issue of Xintelling No. 2 2025](#)
[Xintelling Nyhetsblad Nr 2 2025 EN](#)